Drug Delivery
Oncotelic Therapeutics Targets CNS Drug Delivery as Brain Therapeutics Innovation Accelerates
Oncotelic Therapeutics is leveraging its intranasal nose-to-brain delivery platform to address the challenge of delivering therapeutics across the blood-brain barrier, targeting Alzheimer's disease and biodefense applications in a rapidly evolving biopharma landscape.
CNS Drug Delivery Innovations Address Critical Bottleneck in Biotech Market
Advancements in blood-brain barrier penetration technologies, such as Oncotelic's intranasal nose-to-brain system, are unlocking significant opportunities in the biotech sector by enabling targeted CNS therapies for diseases like Alzheimer's and bolstering biodefense preparedness.
Oncotelic Therapeutics Completes $12.5M Asset Transfer to Lunai Bioworks, Focusing on Nose-to-Brain Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics has transferred worldwide rights to its nose-to-brain delivery system for Alzheimer's and biodefense to Lunai Bioworks in exchange for $12.5 million in preferred stock, enabling it to monetize assets while retaining control for other indications like Parkinson's disease.
Oncotelic and Sapu Bioscience Define Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
Oncotelic Therapeutics and Sapu Bioscience have published a landmark review establishing sub-15 nm nanoparticles as a breakthrough drug delivery platform capable of overcoming limitations of current therapies through enhanced tissue penetration and reduced toxicity.
Oncotelic Therapeutics Featured in Editorial on Nanomedicine Advances in Oncology
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial highlights how its Deciparticle platform represents significant progress in nanomedicine for improving cancer drug delivery and reducing toxicity.
Oncotelic's Nanomedicine Platform Advances Cancer Treatment Through Enhanced Drug Delivery
Oncotelic Therapeutics' Deciparticle platform represents a significant advancement in nanomedicine that improves drug bioavailability and therapeutic effectiveness in oncology treatments.
Nanomedicine Breakthroughs Transform Cancer Drug Delivery and Bioavailability
Recent advancements in nanomedicine technology are revolutionizing oncology treatment by improving drug delivery systems, enhancing bioavailability, and potentially transforming underperforming cancer drugs into effective therapies through platforms like Oncotelic Therapeutics' Deciparticle.
Nanoparticle Breakthrough Offers New Hope for Alcohol-Related Liver Disease Treatment
Researchers have developed innovative nanoparticles that could combat scarring and inflammation in alcohol-related liver disease, potentially creating a treatment template applicable to other organs.
Sapu Nano Receives Australian Ethics Approval for Breast Cancer Drug Trial
Sapu Nano's Sapu003, an injectable form of Everolimus using proprietary nanoparticle technology, has received HREC approval for human clinical trials in Australia, potentially offering more effective breast cancer treatment through improved drug delivery.
Lexaria Bioscience Secures $4 Million in Capital to Advance 2026 Research and Development Initiatives
Lexaria Bioscience Corp. has completed a $4 million registered direct offering, providing crucial funding to advance its 2026 R&D and business development plans for its DehydraTECH drug delivery technology.
Lexaria Bioscience Secures $4 Million in Capital Through Registered Direct Offering
Lexaria Bioscience Corp. has raised $4 million through a registered direct offering, providing crucial working capital to advance its DehydraTECH drug delivery platform technology.
Lexaria's DehydraTECH Shows Enhanced Brain Delivery of Semaglutide in Preclinical Study
Lexaria Bioscience's drug delivery technology demonstrated improved brain distribution of GLP-1 drug semaglutide in rodents, potentially leading to better safety and efficacy for weight loss treatments.
Columbia University Scientists Develop Bacterial Trojan Horse Method to Deliver Anti-Cancer Viruses
Columbia University researchers have engineered bacteria to deliver cancer-killing viruses directly into tumors, bypassing immune system defenses and potentially revolutionizing cancer treatment approaches.
MIT Researchers Develop AI Method to Enhance RNA Nanoparticle Design for Improved Therapeutics
MIT researchers have created an AI-driven approach to optimize RNA nanoparticle design, potentially revolutionizing the delivery of RNA vaccines and treatments while highlighting the growing commercial impact of quantum computing companies like D-Wave.
BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery
BioMed X and Novo Nordisk have partnered to tackle the challenge of oral peptide drug delivery, aiming to improve patient compliance and treatment efficacy through innovative formulation technologies.
Creative Biolabs Enhances Gene Therapy Research with Expanded Liposomal Drug Delivery Services
Creative Biolabs has expanded its liposomal drug delivery services to support advancements in gene therapy, oncology, and molecular medicine, offering customized solutions for research institutions and pharmaceutical industries worldwide.
Oragenics Inc. Advances Toward Phase IIa Concussion Trial with ONP-002
Oragenics Inc. (NYSE American: OGEN) is making significant progress with its lead candidate, ONP-002, aiming to become the first FDA-approved pharmacological treatment for concussion, highlighting the potential of its intranasal delivery technology in transforming neurological care.
Branded Legacy, Inc. to Acquire Bio-Legacy Evaluative Group, Expanding into Intranasal Drug Delivery Market
Branded Legacy, Inc. (OTC: BLEG) has signed a Letter of Intent to acquire Bio-Legacy Evaluative Group, marking a strategic expansion into the intranasal drug delivery sector with a focus on addiction treatments and vaccine accessibility.
Lexaria's DehydraTECH-Semaglutide Shows Promising Reduction in Side Effects Compared to Rybelsus®
Lexaria Bioscience Corp. reports interim results from its Phase 1b study, showing DehydraTECH-semaglutide significantly reduces gastrointestinal and overall side effects compared to Rybelsus®, potentially improving patient adherence to treatment.
Creative Biolabs Enhances Drug Delivery with LipoDrive™ Platform
Creative Biolabs introduces the LipoDrive™ platform, a cutting-edge solution for liposomal drug delivery, addressing the growing demand for precision in biopharmaceutical formulations.
Medicus Pharma Ltd. Develops Novel Non-Invasive Treatment for Basal Cell Carcinoma
Medicus Pharma Ltd. is advancing a revolutionary, non-invasive microneedle patch treatment for basal cell carcinoma, potentially transforming the $15 billion skin cancer treatment market.
Molecular 'Velcro' Breakthrough Promises Advanced Drug Delivery and Biosensing Technologies
Researchers introduce a novel supramolecular chemistry concept called controllable ultrahigh-affinity molecular recognition (CUAMR), which offers unprecedented control in molecular interactions with potential transformative applications in biotechnology and medicine.
Creative Biolabs Advances Antibody-Drug Conjugate Technology with Innovative Engineering Techniques
Creative Biolabs has made significant breakthroughs in antibody-drug conjugate (ADC) development, demonstrating advanced glycosylation engineering and innovative approaches to targeting cancer treatments through bispecific and antibody-oligonucleotide conjugates.
Breakthrough Supramolecular Bakuchiol Offers Gentle, Effective Anti-Aging Solution
Researchers develop a novel supramolecular delivery system for bakuchiol that significantly enhances skin penetration and anti-aging effects while minimizing irritation, potentially transforming the skincare industry.
Creative Biolabs Advances Antibody Technologies to Revolutionize Cancer Treatment
Creative Biolabs is expanding its innovative antibody-related technologies, targeting critical advancements in cancer research and immunotherapy. The company's platforms aim to enhance drug delivery precision and improve therapeutic strategies for previously challenging medical conditions.
Creative Biolabs Advances Drug Delivery with Custom Emulsion Technology
Creative Biolabs has developed innovative emulsion formulations designed to enhance drug stability and bioavailability, offering customized solutions for challenging pharmaceutical delivery systems. The breakthrough technology addresses critical drug solubility issues across various pharmaceutical applications.
Nutriband CEO Gareth Sheridan Named EY Entrepreneur of the Year 2025 Finalist
Nutriband's CEO Gareth Sheridan has been recognized as a finalist in the EY Entrepreneur of the Year Awards, highlighting the company's innovative work in transdermal drug delivery and abuse-deterrent technologies.